...BRCA1 and CDH1). In vivo, it reduced tumor burden and enhanced anti-tumor immunity through MHC-I, PD-L1, and STING pathw...
...BRCA1/2 or PALB2. The primary end point was progression-free survival (PFS) between arms with 0.3 significance. The per-...
...BRCA1, CDH1, PTEN, RARβ), which leads to their suppression, and global hypomethylation that activates oncogenes and prom...
...BRCA1, BRCA2, PALB2) and Fanconi anemia genes (n = 4). Somatic findings established that the germline variants definitiv...
...BRCA1/2 was found in BIA-ALCL. We analyzed the risk of BIA-ALCL occurrence related to BRCA in a large population of wome...
...BRCA1, along with tumor suppressor genes. Nonetheless, it has led to the non-coding portions of the genome garnering rel...
...BRCA1, 25.8 % BRCA2, and 11.3 % other high-risk mutations (RAD51C, PALB2). No tubal lesions were found in 121 cases (91....
...BRCA1 mutation (variant p.S770, c.2309C>G). Mammary-like gland adenocarcinoma of the vulva is a rare but aggressive neop...
...BRCA1, BRCA2, PALB2, TP53 and PTEN, with germline pathogenic or likely pathogenic variants (PVs/LPVs), substantially inc...
...BRCA1/2 carriers is essential for optimized decision-making. This study aimed to examine time trends in the number of re...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
